Shanghai Rendu Biotechnology Co Ltd
SSE:688193
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Shanghai Rendu Biotechnology Co Ltd
Cash from Operating Activities
Shanghai Rendu Biotechnology Co Ltd
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
Shanghai Rendu Biotechnology Co Ltd
SSE:688193
|
Cash from Operating Activities
¥24.4m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
|
S
|
Shanghai Conant Optical Co Ltd
HKEX:2276
|
Cash from Operating Activities
¥477.8m
|
CAGR 3-Years
37%
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
|
|
Autobio Diagnostics Co Ltd
SSE:603658
|
Cash from Operating Activities
¥1.3B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
2%
|
CAGR 10-Years
N/A
|
|
|
Winner Medical Co Ltd
SZSE:300888
|
Cash from Operating Activities
¥1.3B
|
CAGR 3-Years
13%
|
CAGR 5-Years
16%
|
CAGR 10-Years
N/A
|
|
|
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
Cash from Operating Activities
¥1.4B
|
CAGR 3-Years
21%
|
CAGR 5-Years
10%
|
CAGR 10-Years
19%
|
|
|
Intco Medical Technology Co Ltd
SZSE:300677
|
Cash from Operating Activities
¥1.7B
|
CAGR 3-Years
0%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
N/A
|
|
Shanghai Rendu Biotechnology Co Ltd
Glance View
Shanghai Rendu Biotechnology Co., Ltd. develops molecular diagnostic tests. The company is headquartered in Shanghai, Shanghai and currently employs 528 full-time employees. The company went IPO on 2022-03-30. The firm utilizes ribonucleic acid (RNA) isothermal amplification technology to provides multiple series of diagnostic reagents, including respiration series, reproduction series, enterovirus series, blood-borne diseases series and other diagnostic reagents. The firm also designs and manufactures medical instruments. The firm mainly sells its products within domestic market.
See Also
What is Shanghai Rendu Biotechnology Co Ltd's Cash from Operating Activities?
Cash from Operating Activities
24.4m
CNY
Based on the financial report for Dec 31, 2024, Shanghai Rendu Biotechnology Co Ltd's Cash from Operating Activities amounts to 24.4m CNY.
What is Shanghai Rendu Biotechnology Co Ltd's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
12%
Over the last year, the Cash from Operating Activities growth was 42%. The average annual Cash from Operating Activities growth rates for Shanghai Rendu Biotechnology Co Ltd have been -23% over the past three years , 12% over the past five years .
